Evaxion Posts Three-Year Data for Personalized Melanoma Vaccine EVX-01
Evaxion Biotech reports three-year follow-up data for EVX-01, its AI-designed personalized therapeutic vaccine for melanoma, extending durability evidence.
Topic
Adjuvant Therapy
Topic
Adjuvant Therapy
Moderna and Merck Present Phase 3 Melanoma Data on Personalized Cancer Vaccine
Moderna and Merck present Phase 3 melanoma findings for their personalized mRNA cancer vaccine; endpoints, effect sizes and filin…
Chronic Immune-Related Adverse Events Persist After Adjuvant Anti-PD-1 Therapy in Melanoma
Melanoma patients on adjuvant anti-PD-1 therapy can retain chronic immune-related adverse events long after treatment, shifting l…
Keytruda Plus mRNA Vaccine Shows Promise in Skin Cancer Trial
Merck's Keytruda paired with a personalized mRNA vaccine produced 'promising' results in a skin cancer trial, the company reporte…
Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Melanoma Therapy
Chronic immune-related adverse events occur commonly after adjuvant anti–PD-1 therapy for melanoma, The ASCO Post reports, raisin…
Elsner Highlights Personalized mRNA Therapies for High-Risk Melanoma
Dr. Caroline Elsner discusses personalized mRNA-based therapies for high-risk melanoma in an Oncodaily feature, as the adjuvant v…
WVU Medicine Flags mRNA Melanoma Vaccine as News of Note
WVU Medicine spotlights an mRNA melanoma vaccine in its news channel. No new data, but the counseling conversation for dermatolog…
mRNA Vaccine Shows Promise Against Skin Cancer Recurrence
NPR reports a new mRNA vaccine could reduce recurrence and spread of skin cancer, moving mRNA tech from pandemic fame into cutane…
Efficacy vs tolerability in skin cancer: the Schlesinger perspective
AJMC's Todd Schlesinger, MD frames the central trade-off in modern skin cancer care — and why tolerability, not efficacy, increas…
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant t…